The Lantern Vol. 61, No. 1, December 1993

• In Order to Succeed • Essay • Power of Human Self-Interest: Man vs. Car • In Setterich • Wandering Wanda • Maybe Kitchens • Saltiness • Homecoming • Perfect • Sincerely, Jen • A Midterm and a Paper • Prophet Junkie • Soundless Memo • After Ireland, Part 1https://digitalcommons.ursinus.edu/lantern/1142/thumbnail.jp

The Lantern Vol. 62, No. 2, Summer 1995

• In the Season of Grief • Subtleties • Crazehaze • Blacksmith • I Feel Your Weight • L\u27Amour Manque • Sense of You • Greed • Gender (Rolled) • Soliloquy of a Punter • Nightmares • God is a Frisbee • Cleansing • Flat • Chemistry of Mind • Louderback • Ritual • Rebuilding Mother • Scott Lomba • The Acting Bug • Untitled • The Seek • Gluttony • Great South Bay • Archangel • Suburban Zeus • Vespers • At Change of A-Dress • The Hierarchy of Coolness • The Apology • I Know it is Evening There • Pridehttps://digitalcommons.ursinus.edu/lantern/1146/thumbnail.jp

The Lantern Vol. 62, No. 1, December 1994

• Hollow • A Little Knowledge is Dangerous • My Old Block • Life • The Natural Born Fool • Oracle • Formation of a Triangle • Marie on the Beach • The Tweed Derby • Tripping • In Vitro • The Character • Coming Home for Christmas • Unkempt • Too Much • Reimertanti-Ode • Seeds • Secrethttps://digitalcommons.ursinus.edu/lantern/1145/thumbnail.jp

The Grizzly, February 17, 1997

Window Shopping Without the Glass • Ursinus Celebrates Diversity Week • Students Benefit from Internships • Study Abroad: They Don\u27t Call \u27Em Deadlines For Nothing • Campus Apathy on the Issue of Diversity • And the Spirit Moved Them • Caplan Addresses Ethical Issues • Dr. Scott Landis\u27 Resignation Announced • So This is What Security Does: Ursinus\u27 Security Log Returns • Opinion: Greek Speaks Out; Read This if you Think Pledging is Dumb; Come Catch a Square; Perspective from Scotland; Faces of Silence • Defend Yourself! • Keep the Tutorial Program Alive! • Wrestling Bears Win Conference Championship • Women\u27s Basketball Nets Three More Wins • Men\u27s Basketball Drops Two • Gymnasts Leap to Two More Winshttps://digitalcommons.ursinus.edu/grizzlynews/1397/thumbnail.jp

The Lantern Vol. 64, No. 2, Spring 1997

• Year\u27s End, with Resolutions • Addicted • Muerte, Carlos • Motions • At the Wyeth Gallery • Between Contexts • I\u27m Allowed (and More Nonsense) • Wall and Piece • Timekeeper\u27s Workspace • The Process • Second Sex: A Portrait of the Artist as a Woman • On the Side of the Road • Joe • To Matthew Arnold • A Deep Sleep on Hydrocodone • Madness of a Night • Return • The Sudden Grave • A Farce • Twists of Fur • Ambiguity • The Odor of Continuums • My Father\u27s Daughter • The Meaning of Life • I Aim to Tell • Nobody\u27s Fanhttps://digitalcommons.ursinus.edu/lantern/1150/thumbnail.jp

The Lantern Vol. 63, No. 1, Fall 1995

• The Birthday Celebration • Surprise! Surprise! • Oregold • Future of Parenthood #2 • Seeds • How I Spent My Summer Vacation • Random Scenes From 1/2 Hour at Work • Life in the Coal Mines • Driveway • Midnight in the Court of Kings • The Black Quadrilateral • People I Hate to See, But Refuse to Dismiss • Metropolized • Poetry in Motion • Dream #3 • Rhythms • Mercykilling • Untitled • Lupine Lord • At the Bottom of the Cup • House of Commons • Poetry I Can\u27t Standhttps://digitalcommons.ursinus.edu/lantern/1147/thumbnail.jp

The Lantern Vol. 61, No. 2, Summer 1994

• She Was a Woman of Dignity • Retake, Scene 16 • Las Vegas Sweatshirt • Pitcher Hill • In Preparation for Wisdom (Teeth) • Moist Slacks • My Mother\u27s Purse • It Comes and Goes Everyday • The Simplicity of Marriage • The First Performance • Hunger • Pushkin\u27s Dream • Tuesday, October 19 • Poetry of Baseball • Some Things are More Important Than Others • Musician • Of What Befell Our Good Knight • Piranha • Oceans Apart • Brooklyn Cantos • Snowshower • Thankfully in Australia • Toothpaste and Tuna Fish • Living Space • Blue Monday • Afterglow • A Path to Consider • Endless Summer • Scaredy-Cathttps://digitalcommons.ursinus.edu/lantern/1144/thumbnail.jp

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline